PHARMACOKINETIC DRUG INTERACTIONS BETWEEN HMG-COA REDUCTASE INHIBITORS PITAVASTATIN WITH CONCOMITANTLY USED TICAGRELOR

In the present research, the pharmacokinetic Drug-drug interactions between HMG-COA reductase inhibitors Pitavastatin with concomitantly used Ticagrelor have been studied. Pitavastatin is a member of the blood cholesterol lowering medication class of statins while Ticagrelor is a platelet aggregation inhibitor. Combination therapy with statins and other cardiovascular medications is recommended for patients at high atherosclerotic cardiovascular patient's risk. The effect of Pitavastatin on the pharmacokinetics of Ticagrelor was studied on male Wistar rats divided into four different groups, I group is control group, II group of healthy rats administrated with Pitavastatin only in single-dose per day. III group of healthy rats administrated with Ticagrelor in a single dose per day and IV Group of healthy rats administrated with Pitavastatin and Ticagrelor in a single dose per day. The result evaluated by student's paired T-Test and the results indicate no significant increase in peak plasma concentration of Pitavastatin (7.12 +/- 2.12 ng/ml) and Ticagrelor (80.02 +/- 3.03 ng/ml) when administrated alone or in combination (7.32 +/- 1.12 ng/ml and 82.83 +/- 4.13 ng/ml) on first day (day 1). Similarly, no significant increase in peak plasma concentration of Pitavastatin (8.12 +/- 1.12 ng/ml) and Ticagrelor (89.02 +/- 4.13 ng/ml) when administrated alone or in combination (8.32 +/- 1.62 ng/ml and 90.93 +/- 3.25 ng/ml) observed on the eighth (day 8). The study results also indicate no statistically significant difference in t(max), AUC and T-1/2 for both the drug administrated alone and combination treatment.